Early diagnosis and evaluation of therapy in postoperative recurrent cervical cancers by positron emission tomography

Oncology Reports

Volumn 7, Issue 1, 2000, Pages 53-56

  Umesaki, Naohiko ^a   Tanaka, Tetsuji ^a   Miyama, Masato ^a   Tokuyama, Osamu ^a   Kawamura, Naoki ^a   Ogita, Sachio ^a   Kawabe, Jyoji ^a   Okamura, Terue ^a   Koyama, Koichi ^a   Ochi, Hironobu ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; PET; Recurrence; Uterine cervical cancer

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ARTICLE; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; MIDDLE AGED; SCINTISCANNING; TUMOR RECURRENCE; UTERINE CERVIX TUMOR;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TOMOGRAPHY, EMISSION-COMPUTED; UTERINE CERVICAL NEOPLASMS;

EID: 0033629469     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.1.53     Document Type: Article

References (8)

1. Warburg O: On the origin of cancer cells. Science 123: 309-314, 1956.
2. Karlan BY, Hawkins R, Hoh C, Lee M, Tse N, Cane P and Glaspy J: Whole-body positron emission tomography with 2[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 51: 175-181, 1993.
3. Hubner KF, McDonald TW, Niethammer JG, Smith GT, Gould HR and Buonocore E: Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-(18F) deoxyglucose (2-[18F] FDG). Gynecol Oncol 52: 197-204, 1993.
4. Casey MJ, Gupta NC and Muths CK: Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 53: 331-338, 1994.
5. Yoshioka T, Takahashi H, Oikawa H, Maeda S, Ido T, Akaizawa T, Fukuda H and Kanamaru R: Influence of chemotherapy on FDG uptake by human cancer xenografts in nude mice. J Nucl Med 38: 714-717, 1997.
6. Nuutinen JM, Leskinen S, Elomaa I, Minn H, Varpula M, Solin O, Söderströn K-O, Joensuu H and Salminen E: Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET. Eur J Cancer 33: 1234-1241, 1997.
7. Cremerius U, Effert PJ, Adam G, Sabri O, Zimny M, Wagenknecht G, Jakse G and Buell U: FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med 39: 815-822, 1998.
8. Gallagher BM, Flowler JS, Gutterson NI, MacGregor RR, Wan CN and Wolf AP: Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 19: 1154-1161,1978.